Financière de Tubize SA/€TUB
1D1W1MYTD1Y5YMAX
Capital at risk
About Financière de Tubize SA
Financière de Tubize SA is a Belgian holding company established in 1928, serving as the reference shareholder of UCB, a global biopharmaceutical company. Its sole investment is a significant stake in UCB, focusing on long-term value creation through active participation in UCB's strategic decisions. Headquartered in Brussels, Belgium, the company embodies strong family and entrepreneurial values, uniting descendants of UCB's founder, Emmanuel Janssen, and like-minded investors. This strategic positioning provides UCB with the stability necessary for sustained growth and investment in new products for patients with serious illnesses.
- Ticker
- €TUB
- Sector
- Health
- Primary listing
- BSE
- Employees
- 3
- Headquarters
- Brussels, Belgium
- Website
- www.financiere-tubize.be
TUB Metrics
BasicAdvanced
€7.8B
79.33
€2.21
0.39
€0.76
0.43%
Price and volume
Market cap
€7.8B
Beta
0.39
52-week high
€250.00
52-week low
€187.30
Average daily volume
17K
Dividend rate
€0.76
Financial strength
Current ratio
141.923
Quick ratio
141.923
Dividend payout ratio (TTM)
48.87%
Interest coverage (TTM)
-3.03%
Profitability
EBITDA (TTM)
-3.031
Management effectiveness
Return on assets (TTM)
-0.10%
Return on equity (TTM)
5.02%
Valuation
Price to earnings (TTM)
79.334
Price to book
3.94
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
-2,571.659
Free cash flow yield (TTM)
-0.04%
Free cash flow per share (TTM)
-0.068
Dividend yield (TTM)
0.43%
Forward dividend yield
0.43%
Growth
Earnings per share change (TTM)
6.12%
10-year earnings per share growth (CAGR)
-8.11%
3-year dividend per share growth (CAGR)
7.89%
10-year dividend per share growth (CAGR)
8.01%
Bulls say / Bears say
Financière de Tubize became debt-free after repaying €41.3 million in May 2025, reducing interest expenses from €3.48 million in FY 2024 to €1.84 million in FY 2025 and strengthening its capital structure (RNS PDF).
The board proposed a gross dividend of €1.08 per share for FY 2025, a 3.85% increase year-on-year, underscoring its commitment to growing shareholder returns (RNS PDF).
UCB, Financière de Tubize’s sole investment, reported H1 2026 revenue up 22% to €4.27 billion and raised its full-year 2026 guidance for revenue and adjusted EBITDA, supporting NAV expansion for the holding (UCB press release).
Financière de Tubize shares traded at a 44.59% discount to NAV as of December 31, 2025, reflecting persistent market skepticism around its holding structure and governance (Financière de Tubize key figures).
As a mono-holding dependent solely on UCB, Tubize is exposed to UCB’s share-price volatility, evidenced by an over 8% drop in UCB shares on July 30, 2026 despite a guidance upgrade (Reuters).
UCB’s net financial debt surged to €2.821 billion by end-June 2026 from a €7 million net cash position at end-2025 to fund acquisitions and dividends, potentially pressuring future dividend distributions to Financière de Tubize (UCB investors performance).
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2026.
Upcoming events
No upcoming events
Funds containing TUB
AllEURGBPUSD
Fund name | Fund size | €TUB weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 0.26% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 0.26% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.23% |
iShares MSCI EMU ESG Screened€SLMB | €624M | 0.06% |
iShares Core MSCI EMU€CEMU | €6.3B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.